Results 111 to 120 of about 23,143 (200)

Is ondansetron effectief voor negatieve symptomen bij schizofrenie?

Ondansetron (4-8 mg) kan residuele negatieve symptomen bij schizofrenie verbeteren als aanvulling op antipsychotica. Verwacht een bescheiden klinisch voordeel.
Oliver Freudenreich
core   +1 more source

Iron and Other Metal Ions in Human Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Xiaofeng Dai, Jitian Li
wiley   +1 more source

The therapeutic targets and signaling mechanisms of ondansetron in the treatment of critical illness in the ICU

Frontiers in Pharmacology
BackgroundThere is accumulating evidence regarding the benefits of the 5-HT3 receptor antagonist ondansetron for the treatment of critical illness due to its potential anti-inflammatory effect.
Lili Tao, Lili Tao, Zhenhui Zhang, Chuang Li, Minxuan Huang, Ping Chang   +5 more
doaj   +1 more source

Torsades de Pointes after Ondansetron Infusion in 2 Patients

, 2017
Drugs that prolong the electrocardiographic QT interval increase the risk of ventricular arrhythmias, particularly torsades de pointes. Ondansetron, a 5-hydroxytryptamine type 3 receptor antagonist antiemetic, is one such drug.
Sion K. Roy, Tri Trinh, Danny Y. Lee
core   +1 more source

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

Nutrition in Clinical Practice, Volume 41, Issue 5, Page 1318-1333, October 2026.
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation ...
Vikash Singhani, Muhammad Ehsan, Sara Valencia, Ahmed Nadeem, Eisha Moazzam, Winfield Scott Butsch, Samita Garg   +6 more
wiley   +1 more source

Concurrent Treatment With Lorlatinib and Dinutuximab Beta Induced Acute Gastric Dilation in a Pediatric Patient With Neuroblastoma

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Suna Lin, Linjie Li, JiJun Chen, Zhaokun Tao, Lifeng Zhang, Junqing Mao, Jinhu Wang   +6 more
wiley   +1 more source

Perspectives in Pediatric Ambulatory Anesthesia: Part 2—One Center's 15 Year Experience Improving Quality and Safety Outcomes

Pediatric Anesthesia, Volume 36, Issue 10, Page 1196-1206, October 2026.
ABSTRACT Introduction Pediatric ambulatory surgery has become the dominant model of surgical care in the United States, driven primarily by economic forces. There is variability in regional practice patterns, quality improvement cycles, and outcomes. Opportunity exists to overcome knowledge gaps and provide sustainable pathways of quality improvement ...
Jennifer L. Chiem, Elizabeth E. Hansen, Kayla Reece, Samuel M. Vanderhoek, Sanjay R. Parikh, Paul A. Merguerian, Lynn D. Martin   +6 more
wiley   +1 more source

A Team‐Based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH): Real‐World Dosing Patterns and Persistence Among Patients With and Without a History of Methamphetamine Use

Pulmonary Circulation, Volume 16, Issue 4, October 2026.
ABSTRACT Selexipag is an oral prostacyclin receptor agonist approved for pulmonary arterial hypertension (PAH). This single‐center, retrospective study described oral selexipag dosing patterns and persistence, overall and stratified by history of methamphetamine (meth) use, at an expert center in California, USA, using a multidisciplinary, nurse ...
Samuel B. Brusca, Amanda Schnell Heringer, Mark Joshua Lacsamana, Anya Thakur, Jonathan Thomas, Christina Benninger, Gurinderpal Doad, Paul Strachan, Sarah Walden, Ambika Satija, Gayatri Marathe, Henrietta Blinder, Marjolaine Gauthier‐Loiselle, Teresa De Marco   +13 more
wiley   +1 more source

Nausea and vomiting of pregnancy in relation to fear of childbirth: Evidence from a Finnish cohort

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 10, Page 2005-2011, October 2026.
Moderate or severe nausea and vomiting of pregnancy (NVP) is associated with a higher likelihood of fear of childbirth compared with no or mild NVP. The findings suggest that more severe NVP is linked to a greater psychological burden and may affect women's perception of childbirth.
Anna Murto, Linda Laitinen, Eeva Terävä‐Utti, Miina Nurmi, Mari Koivisto, Päivi Polo‐Kantola   +5 more
wiley   +1 more source

Comparing Intravenous Lidocaine, Ondansetron and Their Combination on Reducing Pain of Injection of Propofol

Archives of Anesthesia and Critical Care, 2016
Background: Propofol is a widely used intravenous anesthetic drug. One of its side effects is pain during injection. We investigate the effects of intravenous ondansetron, lidocaine, and their combination on pain reduction of intravenous propofol ...
Sussan Soltani Mohammadi, Maliheh Khosravi, Gita Shoeibi   +2 more
doaj